The Technical Analyst
Biocept Inc [BIOC]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Biocept Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-13.88% $0.435
America/New_York / 24 okt 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1.142 mill |
| EPS: | -48.17 |
| P/E: | -0.0090 |
| Earnings Date: | Nov 19, 2023 |
| SharesOutstanding: | 2.63 mill |
| Avg Daily Volume: | 2.16 mill |
| RATING 2023-11-21 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0090 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0090 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0960 - 0.202 ( +/- 281.13%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-16 | Walsh Robert | Sell | 806 | Employee Stock option (right to buy) |
| 2022-11-17 | Dao-haddock Quyen Thi | Buy | 10 000 | Employee Stock Option (right to buy) |
| 2022-11-17 | Dao-haddock Quyen Thi | Buy | 0 | |
| 2022-11-17 | Dao-haddock Quyen Thi | Buy | 0 | |
| 2022-07-08 | Chandler Marsha Alpert | Buy | 10 000 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 93.06 |
| Last 94 transactions |
| Buy: 4 462 700 | Sell: 1 536 257 |
Forecast:
01:40 - $0.390
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.435 (-13.88% ) |
| Volume | 0.672 mill |
| Avg. Vol. | 2.16 mill |
| % of Avg. Vol | 31.13 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BIOC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BIOC
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
Latest Press Releases
2023-09-21 08:00:00 - Press Release
Enrollment Completed In The Feasibility Phase Of The Foresee Clinical Trial With Biocept's Cnside™ Assay To Evaluate Patients With Leptomeningeal Metastases
San diego--(business wire)---- $bioc #csf--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (nsclc) who have suspicious or confirmed leptomeningeal metastases (lm) in the feasibility phase of its prospective foresee clinical trial (nct0414123). this trial is evaluating the performance of biocept's proprietary cnside assay in monitoring the response to therapy of lm, a c.
2023-09-08 08:00:00 - Press Release
Biocept Signs Cnside™ Licensing Agreement With Plus Therapeutics
San diego--(business wire)---- $bioc #csf--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for cnside™ with plus therapeutics, inc. (nasdaq: pstv) (plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in june 2022. plus is using cnside in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or m.
2023-09-05 08:00:00 - Press Release
Biocept To Participate In The H.c. Wainwright Global Investment Conference
San diego--(business wire)--biocept, inc. (nasdaq: bioc) (“biocept” or the “company”), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the h.c. wainwright 25th annual global investment conference being held september 11-13, 2023. a webcast of the biocept presentation will be available on the events & presentation section of the company's website beginning monday, september 11 at 7:00 a.m. eastern time. management is ava.
2023-08-25 08:00:00 - Press Release
Biocept To Hold Business Update Conference Call On August 30, 2023
San diego--(business wire)--biocept, inc. (nasdaq: bioc) management will hold a conference call on august 30, 2023, beginning at 4:00 p.m. eastern time (1:00 p.m. pacific time) to provide a business update and to answer questions. participants can pre-register for the conference call here. callers who pre-register will be given a conference passcode and unique pin to gain immediate access to the call and bypass the live operator. participants may pre-register at any time, including up to and af.
2023-08-14 16:05:00 - Press Release
Biocept Reports Second Quarter 2023 Financial Results
San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended june 30, 2023 and provides a business update. “biocept's primary focus is establishing our proprietary cerebrospinal fluid assay cnside™ as standard of care. we continue to diligently work towards submission to the national comprehensive cancer network® (nccn®) for consideration to include cnside in their.
Latest News
2023-08-30 20:38:10 - Seeking Alpha
Biocept, Inc. (BIOC) Business Update Conference Call (Transcript)
Biocept, Inc. (NASDAQ:BIOC ) Business Update Conference Call August 30, 2023 4:00 PM ET Company Participants Jody Cain - LHA Antonino Morales - President, CEO Dr. Barbara Blouw - VP, Clinical Development Dr. Seema Nagpal - Clinical Professor of Neurology-Stanford University Dr. Philippe Marchand - Chief Operating Officer Robert Walsh - Vice President, Controller Darrell Taylor - Chief Legal and Compliance Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Michael Okunewitch - Maxim Group Operator Welcome to the Biocept Business Update Conference Call. [Operator Instructions].
2023-08-25 08:00:00 - Business Wire
Biocept to Hold Business Update Conference Call on August 30, 2023
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer questions. Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and af.
2023-08-25 07:20:36 - InvestorPlace
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.
2023-08-14 08:40:19 - Proactive Investors
Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference
Biocept Inc (NASDAQ:BIOC) said that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 Society for Neuro-Oncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Cancer Conference which was held in San Fransico between August 10 and 12. The two abstracts presented were titled: “The HER2 Flip: HER2 Amplification of Tumor Cells in the Cerebrospinal Fluid (CSF-TCs) of Patients with Leptomeningeal Metastasis having solid tumors; implications for treating the LM tumor with anti-HER2 therapy,” and “Circulating tumor cell analysis from the cerebrospinal fluid informs early diagnosis, treatment and prognosis in leptomeningeal carcinomatosis (LMC).
2023-06-21 08:14:53 - Proactive Investors
Biocept appoints Antonino Morales as president and chief executive officer
Biocept Inc (NASDAQ:BIOC) has announced the appointment of Antonino Morales as its president and chief executive officer, effective immediately. Morales, who has been serving as the company's interim chief financial officer since February 2022 and as a director of the company since July 2021, will now take on the leadership role.
2023-06-14 16:05:00 - Business Wire
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces that management will present at the Maxim Group Virtual Healthcare Conference hosted by M-Vest on Tuesday, June 20 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time). Biocept's discussion will be hosted by Maxim Group Senior Research Analyst Michael Okunewitch. Registration information to become an M-Vest member for access to t.
2023-06-05 09:36:49 - Proactive Investors
Biocept says poster presentation at ASCO highlights impressive performance of CNSide assay in detecting leptomeningeal metastases
Biocept Inc (NASDAQ:BIOC) said that a poster presentation at the annual American Society of Clinical Oncology (ASCO) demonstrates the impressive ability of the company's cerebrospinal fluid assay CNSide to detect rates of leptomeningeal metastases, compared with standard CSF cytology from lumbar puncture. In a nutshell, leptomeningeal metastases (LM), is a type of cancer in the cerebrospinal fluid and membranes that surround a person's brain and spinal cord (the leptomeninges).
2023-05-25 08:56:07 - InvestorPlace
Why Is Biocept (BIOC) Stock Down 42% Today?
Biocept (NASDAQ: BIOC ) stock is falling hard on Thursday after the company revealed details of a public offering for its shares. Biocept is offering 1,176,470 shares of its common stock and warrants for up to 2,352,940 shares of BIOC stock.
2023-05-17 09:06:54 - Proactive Investors
Biocept shares to commence trading on split-adjusted basis
Biocept has announced a one-for-thirty reverse stock split which became effective at 4:05pm Eastern Time on May 16, 2023. The company's common stock will begin trading on a split-adjusted basis as of the open of the market on May 17 under Biocept's existing ticker symbol “BIOC.
2023-04-17 16:47:52 - Proactive Investors
Biocept outlines plans to get CNSide assay system commercially available, looks back on the 2022 financial year
Biocept Inc (NASDAQ:BIOC), which develops and commercializes molecular diagnostic assays, revealed new details about its plans to get its CNSide assay system off the ground in 2023. Interim CEO Samuel Riccitelli told shareholders that the company decided that the best course of action is to further develop and commercialize CNSide while pursuing various options to extend its cash runway.